Marginal structural cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort

American Journal of Epidemiology

Volumn 180, Issue 2, 2014, Pages 160-171

  Karim, Mohammad Ehsanul ^a   Gustafson, Paul ^a   Petkau, John ^a   Zhao, Yinshan ^a   Shirani, Afsaneh ^a   Kingwell, Elaine ^a   Evans, Charity ^a   Van Der Kop, Mia ^a   Oger, Joel ^a   Tremlett, Helen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

bias (epidemiology); causality; confounding factors (epidemiology); epidemiologic methods; inverse probability weighting; marginal structural Cox model; multiple sclerosis; survival analysis

Indexed keywords

BETA INTERFERON;

COHORT ANALYSIS; DATA SET; DISEASE PREVALENCE; EPIDEMIOLOGY; ESTIMATION METHOD; NUMERICAL MODEL; POLLUTION EXPOSURE; STABILIZATION; SURVIVAL; WEIGHT;

ADULT; ARTICLE; CANADA; CLINICAL PRACTICE; DISABILITY; DISEASE COURSE; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PROPORTIONAL HAZARDS MODEL; RELAPSE; SENSITIVITY ANALYSIS; SURVIVAL RATE;

BRITISH COLUMBIA; CANADA;

BIAS (EPIDEMIOLOGY); CAUSALITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); EPIDEMIOLOGIC METHODS; INVERSE PROBABILITY WEIGHTING; MARGINAL STRUCTURAL COX MODEL; MULTIPLE SCLEROSIS; SURVIVAL ANALYSIS;

BRITISH COLUMBIA; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROBABILITY; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 84904018610     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu125     Document Type: Article

References (52)

1. World Health Organization and Multiple Sclerosis International Federation. Atlas: Multiple Sclerosis Resources in the World 2008. Geneva, Switzerland: World Health Organization; 2008.
2. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655-661.
3. IFNB Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45(7):1277-1285.
4. Multiple Sclerosis Collaborative Research Group. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285-294.
5. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504.
6. Once Weekly Interferon for MS Study Group. Evidence of interferon β-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology. 1999;53(4):679-686.
7. Brown MG, Kirby S, Skedgel C, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology. 2007;69(15):1498-1507.
8. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann Neurol. 2007;61(4):300-306.
9. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012;308(3): 247-256.
10. Renoux C, Suissa S. Immortal time bias in the study of effectiveness of interferon-β in multiple sclerosis. Ann Neurol. 2008;64(1):109-110.
11. Koch M, Mostert J, De Keyser J, et al. Interferon-β treatment and the natural history of relapsing-remitting multiple sclerosis. Ann Neurol. 2008;63(1):125-126.
12. Derfuss T, Kappos L. Evaluating the potential benefit of interferon treatment in multiple sclerosis. JAMA. 2012;308(3): 290-291.
13. Goodin DS, Reder AT, Cutter G. Treatment with interferon beta for multiple sclerosis [letter]. JAMA. 2012;308(16):1627-1628.
14. Shirani A, Petkau J, Tremlett H. Treatment with interferon beta for multiple sclerosis-reply [letter]. J Am Med Assoc. 2012; 308(16):1627-1628.
15. Greenberg BM, Balcer L, Calabresi PA, et al. Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol. 2013;70(2):248-251.
16. Shirani A, Zhao Y, Karim ME, et al. Interferon beta and long-term disability in multiple sclerosis. JAMA Neurol. 2013; 70(5):651-653.
17. Coles A. Multiple sclerosis: the bare essentials. Pract Neurol. 2009;9(2):118-126.
18. Shirani A, Zhao Y, Karim ME, et al. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study. Eur J Neurol. 2014;21(6):835-844.
19. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561-570.
20. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc. 2001;96(454):440-448.
21. Young JG, Hernán MA, Picciotto S, et al. Relation between three classes of structural models for the effect of a time-varying exposure on survival. Lifetime Data Anal. 2010;16(1):71-84.
22. Xiao Y, Abrahamowicz M, Moodie EE. Accuracy of conventional and marginal structural Cox model estimators: a simulation study. Int J Biostat. 2010;6(2):Article 13.
23. Westreich D, Cole SR, Schisterman EF, et al. A simulation study of finite-sample properties of marginal structural Cox proportional hazards models. Stat Med. 2012;31(19):2098-2109.
24. Havercroft WG, Didelez V. Simulating from marginal structural models with time-dependent confounding. Stat Med. 2012; 31(30):4190-4206.
25. Xiao Y, Moodie EEM, Abrahamowicz M. Comparison of approaches to weight truncation for marginal structural Cox models. Epidemiol Methods. 2013;2(1):1-20.
26. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-1452.
27. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology. 2006;66(2):172-177.
28. Tremlett H, Yousefi M, Devonshire V, et al. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology. 2009;73(20):1616-1623.
29. Tremlett H, Zhao Y, Joseph J, et al. Relapses in multiple sclerosis are age-and time-dependent. J Neurol Neurosurg Psychiatry. 2008;79(12):1368-1374.
30. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-560.
31. Robins JM. Marginal structural models versus structural nested models as tools for causal inference. In: Halloran ME, Berry D, eds. Statistical Models in Epidemiology, the Environment and Clinical Trials. New York, NY: Springer-Verlag; 1999:95-134.
32. Robins JM. Association, causation, and marginal structural models. Synthese. 1999;121(1):151-179.
33. Robins JM, Greenland S, Hu FC. Estimation of the causal effect of a time-varying exposure on the marginal mean of a repeated binary outcome. J Am Stat Assoc. 1999;94(447): 687-700.
34. Cook NR, Cole SR, Hennekens CH. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Am J Epidemiol. 2002;155(11):1045-1053.
35. Cole SR, Hernán MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol. 2003;158(7):687-694.
36. Gran JM, Røysland K, Wolbers M, et al. A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. Stat Med. 2010;29(26):2757-2768.
37. McCulloch M, Broffman M, van der Laan M, et al. Lung cancer survival with herbal medicine and vitamins in a whole-systems approach: ten-year follow-up data analyzed with marginal structural models and propensity score methods. Integr Cancer Ther. 2011;10(3):260-279.
38. Ali RA, Ali MA, Wei Z. On computing standard errors for marginal structural Cox models. Lifetime Data Anal. 2014; 20:106-131.
39. Westreich D, Cole SR, Tien PC, et al. Time scale and adjusted survival curves for marginal structural Cox models. Am J Epidemiol. 2010;171(6):691-700.
40. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6): 656-664.
41. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2012. (http://www.R-project.org/). (Accessed January 1, 2014).
42. Hernán MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health. 2006; 60(7):578-586.
43. Platt RW, Delaney JA, Suissa S. The positivity assumption and marginal structural models: the example of warfarin use and risk of bleeding. Eur J Epidemiol. 2012;27(2): 77-83.
44. van der Wal WM, Noordzij M, Dekker FW, et al. Comparing mortality in renal patients on hemodialysis versus peritoneal dialysis using a marginal structural model. Int J Biostat. 2010; 6(1):Article 2.
45. Robins J, Orellana L, Rotnitzky A. Estimation and extrapolation of optimal treatment and testing strategies. Stat Med. 2008; 27(23):4678-4721.
46. Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: a critique. Neurology. 1988;38(11): 1793-1798.
47. Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010;81(8):907-912.
48. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer-Verlag; 2001.
49. ThompsonWA Jr. On the treatment of grouped observations in life studies. Biometrics. 1977;33(3):463-470.
50. D'Agostino RB, Lee ML, Belanger AJ, et al. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med. 1990;9(12): 1501-1515.
51. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10(1):37-48.
52. Glymour MM. Using causal diagrams to understand common problems in social epidemiology. In: Oakes JM, Kaufman JS, eds. Methods in Social Epidemiology. San Francesco, CA: Jossey-Bass/Wiley; 2006:393-428.